From Inquiry to Investigation to Insight (I3): Clinical Clarity in Non-small Cell Lung Cancer
credits/contact hours

Learn From the Experts About Clinical Clarity in NSCLC

Learn strategies to improve outcomes for your patients with non-small cell lung cancer.


Upon completion of this activity, participants should be better able to:

  • Evaluate recent updates regarding biomarker testing and molecular profiling used to guide management decisions for metastatic NSCLC
  • Devise treatment plans for patients with locally advanced NSCLC
  • Evaluate efficacy and safety data supporting the use of targeted and immune checkpoint inhibitor therapy used to treat NSCLC
  • Select therapy in accordance with evidence-based best practices
  • Apply clinical approaches to mitigate adverse events associated with targeted and ICI therapy
  • Manage drug–drug and drug–disease interactions in NSCLC 
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.